These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35674123)

  • 1. Challenges of Conducting Value Assessment for Comprehensive Genomic Profiling.
    Tarride JE; Gould T; Thomas DM
    Int J Technol Assess Health Care; 2022 Jun; 38(1):e57. PubMed ID: 35674123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unlocking Access to Broad Molecular Profiling: Benefits, Barriers, and Policy Solutions.
    Thomas DM; Hackett JM; Plestina S
    Public Health Genomics; 2021 Dec; ():1-10. PubMed ID: 34959236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective.
    Reitsma M; Fox J; Borre PV; Cavanaugh M; Chudnovsky Y; Erlich RL; Gribbin TE; Anhorn R
    J Manag Care Spec Pharm; 2019 May; 25(5):601-611. PubMed ID: 30632889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Systematic Review of Value Criteria for Next-Generation Sequencing/Comprehensive Genomic Profiling to Inform Value Framework Development.
    Augustovski F; Colaci C; Mills M; Chavez D; Argento F; Alfie V; Pichon Riviere A; Kanavos P; Alcaraz A
    Value Health; 2024 May; 27(5):670-685. PubMed ID: 38403113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health technology assessment of tests for SARS-CoV-2 and treatments for COVID-19: A proposed approach and best-practice recommendations.
    Elvidge J; Summerfield A; Knies S; Németh B; Kaló Z; Goettsch W; Dawoud DM;
    Int J Technol Assess Health Care; 2023 Apr; 39(1):e24. PubMed ID: 37092749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies.
    Gaultney JG; Bouvy JC; Chapman RH; Upton AJ; Kowal S; Bokemeyer C; Solà-Morales O; Wolf J; Briggs AH
    Appl Health Econ Health Policy; 2021 Sep; 19(5):625-634. PubMed ID: 34028672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health technology assessment and private payers's coverage of personalized medicine.
    Trosman JR; Van Bebber SL; Phillips KA
    Am J Manag Care; 2011 May; 17 Suppl 5 Developing():SP53-60. PubMed ID: 21711078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
    Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
    J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Models and applications for measuring the impact of health research: update of a systematic review for the Health Technology Assessment programme.
    Raftery J; Hanney S; Greenhalgh T; Glover M; Blatch-Jones A
    Health Technol Assess; 2016 Oct; 20(76):1-254. PubMed ID: 27767013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of the National Institute for Health Research Health Technology Assessment programme, 2003-13: a multimethod evaluation.
    Guthrie S; Bienkowska-Gibbs T; Manville C; Pollitt A; Kirtley A; Wooding S
    Health Technol Assess; 2015 Aug; 19(67):1-291. PubMed ID: 26307643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges.
    Daubner-Bendes R; Kovács S; Niewada M; Huic M; Drummond M; Ciani O; Blankart CR; Mandrik O; Torbica A; Yfantopoulos J; Petrova G; Holownia-Voloskova M; Taylor RS; Al M; Piniazhko O; Lorenzovici L; Tarricone R; Zemplényi A; Kaló Z
    Front Public Health; 2020; 8():612410. PubMed ID: 33490024
    [No Abstract]   [Full Text] [Related]  

  • 13. Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective.
    Quinn C; Garrison LP; Pownell AK; Atkins MB; de Pouvourville G; Harrington K; Ascierto PA; McEwan P; Wagner S; Borrill J; Wu E
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanding health technology assessment towards broader value: Ireland as a case study.
    Kinchin I; Walshe V; Normand C; Coast J; Elliott R; Kroll T; Kinghorn P; Thompson A; Viney R; Currow D; O'Mahony JF
    Int J Technol Assess Health Care; 2023 May; 39(1):e26. PubMed ID: 37129030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system.
    Perdrizet K; Stockley TL; Law JH; Smith A; Zhang T; Fernandes R; Shabir M; Sabatini P; Youssef NA; Ishu C; Li JJ; Tsao MS; Pal P; Cabanero M; Schwock J; Ko HM; Boerner S; Ruff H; Shepherd FA; Bradbury PA; Liu G; Sacher AG; Leighl NB
    Cancer Treat Res Commun; 2022; 31():100534. PubMed ID: 35278845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health technology assessment in the era of personalized health care.
    Becla L; Lunshof JE; Gurwitz D; Schulte In den Bäumen T; Westerhoff HV; Lange BM; Brand A
    Int J Technol Assess Health Care; 2011 Apr; 27(2):118-26. PubMed ID: 21450126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value added medicines: what value repurposed medicines might bring to society?
    Toumi M; Rémuzat C
    J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
    [No Abstract]   [Full Text] [Related]  

  • 18. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
    Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
    Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget Impact Analysis of Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer in Taiwan.
    Tsai YL; Chang CJ
    Value Health Reg Issues; 2023 May; 35():48-56. PubMed ID: 36863067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation Road Map of Health Technology Assessment in Middle-Income Countries: The Case of Jordan.
    Almomani E; Alabbadi I; Fasseeh A; Al-Qutob R; Al-Sharu E; Hayek N; Tarawneh MR; Kaló Z
    Value Health Reg Issues; 2021 Sep; 25():126-134. PubMed ID: 34015521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.